Identification of an OmpW homologue in Burkholderia pseudomallei, a protective vaccine antigen against melioidosis(103 visite) Casey WT, Spink N, Cia F, Collins C, Romanò MF, Berisio R, Bancroft GJ, Mcclean S
Vaccine (ISSN: 0264-410x), 2016 May 17; 34(23): 2616-2621.
Tipo di articolo: Journal Article,
Impact factor: 3.235, Impact factor a 5 anni: 3.259
Url: Non disponibile.
Parole chiave: Burkholderia Cepacia Complex, Burkholderia Pseudomallei, Recombinant Subunit Antigen,
*** IBB - CNR *** Centre of Microbial Host Interactions, ITT Dublin, Tallaght, Dublin 24, Ireland., Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom., Institute of Biostructures and Bioimaging, National Research Council, Via Mezzocannone 16, I-80134 Naples, Italy., Centre of Microbial Host Interactions, ITT Dublin, Tallaght, Dublin 24, Ireland. Electronic address: Siobhan.email@example.com.,
Burkholderia pseudomallei is the causative agent of melioidosis, which is associated with a range of clinical manifestations, including sepsis and fatal pneumonia and is endemic in Southeast Asia and Northern Australia. Treatment can be challenging and control of infection involves prolonged antibiotic therapy, yet there are no approved vaccines available to prevent infection. Our aim was to develop and assess the potential of a prophylactic vaccine candidate targeted against melioidosis. The identified candidate is the 22kDa outer membrane protein, OmpW. We previously demonstrated that this protein was immunoprotective in mouse models of Burkholderia cepacia complex (Bcc) infections. We cloned Bp_ompW in Escherichia coli, expressed and purified the protein. Endotoxin free protein administered with SAS adjuvant protected Balb/C mice (75% survival) relative to controls (25% survival) (p<0.05). A potent serological response was observed with IgG2a to IgG1 ratio of 6.0. Furthermore C57BL/6 mice were protected for up to 80 days against a lethal dose of B. pseudomallei and surpassed the efficacy of the live attenuated 2D2 positive control. BpompW is homologous across thirteen sequenced B. pseudomallei strains, indicating that it should be broadly protective against B. pseudomallei. In conclusion, we have demonstrated that BpOmpW is able to induce protective immunity against melioidosis and is likely to be an effective vaccine antigen, possibly in combination with other subunit antigens.